Previous 10 | Next 10 |
Aclaris Therapeutics ( ACRS +22.4% ) is up on almost 30% higher volume following its Q4 report and 2019 outlook. Highlights: More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Aclaris Therapeutics (NASDAQ: ACRS ): Q4 GAAP EPS of -$0.99 misses by $0.07 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Product Sales of $3.9 Million for Fiscal Year 2018 Initiates Financial Guidance for Full Year 2019 Management to Host Conference Call at 8:00 AM ET today WAYNE, Pa., March 18, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical...
WAYNE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Aclaris Therapeutics, Inc. (NASDAQ: ACRS) please note that in the first paragraph of the release, it should read "before U.S. financial markets open," not "be...
WAYNE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced it will report financial results for the fourth quarter and full year 2018, Monday,...
WAYNE, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced that it received approval from the Swedish Medical Products Agency to market ESK...
Phase 2 Clinical Study Results in Treatment of Common Warts Selected for Oral Presentations WAYNE, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that posters summarizing ...
WAYNE, Pa., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatology...
Aclaris Therapeutics (NASDAQ: ACRS ): Q3 GAAP EPS of -$1.06 beats by $0.20 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significa...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...